Eiger BioPharmaceuticals (NASDAQ:EIGR) Now Covered by Analysts at StockNews.com
StockNews.com assumed coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR – Free Report) in a research report released on Saturday morning. The firm issued a sell rating on the biotechnology company’s stock. Several other equities analysts also recently weighed in on EIGR. Citigroup reduced their target price on Eiger BioPharmaceuticals from $4.00 to $3.00 and set […]